Entities / Company
Avadel Pharmaceuticals.
specialty pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 32
What's happening
Gone quiet
No new reports in 90+ days-
FDA approval of LUMRYZ™ is contingent on sale terms, with Alkermes proposed as the buyer of Avadel Pharmaceuticals.Some support3 reports2 developments inside
-
Jazz Pharmaceuticals sued over LUMRYZ approval, which the FDA granted for narcolepsy treatment, leading to court rulings in the D.C. circuit.Some support2 reports
-
ASL Strategic Value Fund found inconsistencies in Avadel Pharmaceuticals' reported vote tallies.Some support2 reports1 development inside
-
A proxy battle has been launched concerning alleged missteps in the launch of the drug Lumryz.Speculative1 report
-
Eric Ende bought shares of Avadel Pharmaceuticals on July 7, 2025.Speculative1 report
-
FDA granted Orphan Drug Designation for LUMRYZ, a drug developed by Avadel Pharmaceuticals.Some support1 report
-
Avadel Pharmaceuticals was ranked in the medical drugs industry in August 2025.Some support2 reports
-
Avadel Pharmaceuticals sought FDA approval for new indications and secured an exclusive licensing deal with XWPharma.Some support1 report1 development inside
-
Avadel Pharmaceuticals secured an exclusive global license agreement with XWPharma for the development of valiloxybate.Some support1 report
-
Avadel Pharmaceuticals, an Ireland-based biopharmaceutical company, disclosed a Form 13F filing with the SEC.Some support2 reports
-
Avadel Pharmaceuticals plans to present data at World Sleep 2025 in Singapore.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Avadel Pharmaceuticals this week
News at the entities that move Avadel Pharmaceuticals most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Avadel Pharmaceuticals
-
Ireland Shared contextIreland is working to improve governmental transparency by enhancing its digital services.Moves Avadel Pharmaceuticals
Connections
The 3 strongest of 32, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
XWPHARMA Transactional
XWPHARMA granted Avadel Pharmaceuticals an exclusive global license agreement for the development of valiloxybate.
-
FDA Structural
The FDA formally regulates Avadel Pharmaceuticals, granting approvals and designations for its commercial products.
-
Ireland Shared context
Avadel Pharmaceuticals is based in Ireland.
History
Events by the month they beganJune 2026
11 events- FDA approval of LUMRYZ™ is contingent on sale terms, with Alkermes proposed as the buyer of Avadel Pharmaceuticals.
- Jazz Pharmaceuticals sued over LUMRYZ approval, which the FDA granted for narcolepsy treatment, leading to court rulings in the D.C. circuit.
- ASL Strategic Value Fund found inconsistencies in Avadel Pharmaceuticals' reported vote tallies.
- A proxy battle has been launched concerning alleged missteps in the launch of the drug Lumryz.
- Eric Ende bought shares of Avadel Pharmaceuticals on July 7, 2025.
- FDA granted Orphan Drug Designation for LUMRYZ, a drug developed by Avadel Pharmaceuticals.
- Avadel Pharmaceuticals was ranked in the medical drugs industry in August 2025.
- Avadel Pharmaceuticals sought FDA approval for new indications and secured an exclusive licensing deal with XWPharma.
- Avadel Pharmaceuticals secured an exclusive global license agreement with XWPharma for the development of valiloxybate.
- Avadel Pharmaceuticals, an Ireland-based biopharmaceutical company, disclosed a Form 13F filing with the SEC.
- Avadel Pharmaceuticals plans to present data at World Sleep 2025 in Singapore.